(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
IMMIX Biopharma's earnings in 2025 is -$20,896,913.On average, 1 Wall Street analyst forecast IMMX's earnings for 2025 to be -$17,283,922, with the lowest IMMX earnings forecast at -$17,283,922, and the highest IMMX earnings forecast at -$17,283,922.
In 2026, IMMX is forecast to generate -$18,120,240 in earnings, with the lowest earnings forecast at -$18,120,240 and the highest earnings forecast at -$18,120,240.